Recent Updates — NEOG
Neogen Corporation shareholders approved the Amended and Restated Omnibus Incentive Plan at the annual meeting on October 1, 2026. The plan amends the existing 2023 Omnibus Incentive Plan and authorizes the issuance of up to 31,350,000 shares for equity-based awards, including stock options, restricted stock units, and performance stock units, available to employees and non-employee directors. Neogen Corporation develops and markets biological test kits and sanitizers for food safety.
Neogen Corporation reported first-quarter fiscal 2027 results with total revenues of $222.8 million, a 6.5% increase from the prior year period. The company posted a net loss of $11.9 million, or $(0.05) per diluted share, compared to net income of $36.3 million in the previous quarter. Adjusted net income rose to $17.5 million, or $0.08 per diluted share, driven by higher EBITDA and lower interest expenses. Gross margin improved to 47.4% from 45.4%, while adjusted EBITDA reached $41.6 million with an 18.7% margin. Management raised full-year fiscal 2027 financial guidance, now expecting revenue between $885 million and $890 million and adjusted EBITDA between $181 million and $183 million. Neogen operates in the food safety and animal health sectors, providing detection products, diagnostics, and related services.
On August 3, 2026, Mr. Thierry Bernard resigned from the Board of Directors of Neogen Corporation. This executive departure is a material event requiring disclosure under Item 5.02 of Form 8-K. Neogen Corporation operates in the food safety and animal health industry, providing diagnostic tests, sampling systems, and sanitation products.
Neogen Corporation reported fiscal fourth quarter and full year 2026 results on July 30, 2026. Q4 revenue was $225.3 million (Core Growth 4.3%), with Food Safety up 3.1% and Animal Safety down 8.2%. The company posted a net loss of $11.3 million ($0.05 per share) but Adjusted Net Income of $18.7 million ($0.09 per share). Full year revenue was $870.4 million with a net loss of $7.9 million. Neogen provided FY2027 guidance for revenue of $880-$885 million and Adjusted EBITDA of $180-$182 million. The company is progressing toward the sale of its Genomics business to Zoetis Inc., with regulatory reviews ongoing in Australia and New Zealand, targeting closure by H1 FY27 for approximately $140 million net proceeds. Manufacturing transitions for Petrifilm are scheduled to begin in November 2026. Neogen Corporation operates in the food safety and animal safety solutions industry.